Chemotherapy of prostate cancer: Present and future

被引：18

作者：

Donald Trump

Yiu-Keung Lau

机构：

[1] Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, 14263, NY

来源：

Current Urology Reports | 2003年 / 4卷 / 3期

关键词：

Clin Oncol; Docetaxel; Estramustine; Mitoxantrone; Prostate Cancer;

D O I：

10.1007/s11934-003-0074-3

中图分类号：

学科分类号：

摘要：

The role of chemotherapy in prostate cancer continues to evolve. In men with symptomatic androgen-independent prostate cancer, significant reduction in pain and analgesic requirements are achievable with mitoxantrone and glucocorticoid combinations compared with glucocorticoids alone. However, survival rates are not improved. Taxane-based combinations with estramustine phosphate or other new agents show promise. Prostate-specific antigen response rates with these combinations appear to be 1.5 to 2 times more frequent than with mitoxantrone-based combinations. Randomized trials of taxane versus mitoxantrone-based therapies are underway. New agents and applications of current agents in adjuvant settings should be explored if survival in men with prostate cancer is to be improved. © 2003, Current Science Inc.

引用

页码：229 / 232

页数：3

共 33 条

[1]

Kantoff P.W., Halabi S., Conaway M., Et al., Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study, J Clin Oncol, 17, pp. 2506-2513, (1999)

[2]

Tannock I.F., Osoba D., Stockler M.R., Et al., Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points, J Clin Oncol, 14, pp. 1756-1764, (1996)

[3]

Hudes G., Einhorn L., Ross E., Et al., Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial, J Clin Oncol, 17, pp. 3160-3166, (1999)

[4]

Oh W.K., Kantoff P.W., Management of hormone refractory prostate cancer: current standards and future prospects, J Urol, 160, pp. 1220-1229, (1998)

[5]

Culine S., Droz J.P., Chemotherapy in advanced androgen-independent prostate cancer 1990–1999: a decade of progress?, Ann Oncol, 11, pp. 1523-1530, (2000)

[6]

Benson R., Hartley-Asp B., Mechanisms of action and clinical uses of estramustine, Cancer Invest, 8, pp. 375-380, (1990)

[7]

Iversen P., Rasmussen F., Asmussen C., Et al., Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. Danish Prostatic Cancer Group, J Urol, 157, pp. 929-934, (1997)

[8]

Roth B.J., Yeap B.Y., Wilding G., Et al., Taxol in advanced, hormone-refractory carcinoma of the prostate: a phase II trial of the Eastern Cooperative Oncology Group, Cancer, 72, pp. 2457-2460, (1993)

[9]

Petrylak D.P., Macarthur R.B., O'Connor J., Et al., Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer, J Clin Oncol, 17, pp. 958-967, (1999)

[10]

Savarese D.M., Halabi S., Hars V., Et al., Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B, J Clin Oncol, 19, pp. 2509-2516, (2001)

← 1 2 3 4 →